Abstract
Historically, the G protein-coupled receptor (GPCR) protein family has proven to be an extremely tractable target class (1). It is estimated that approximately one-half of all drugs currently marketed exert their actions, either directly or indirectly, via GPCRs (2). Given the potential commercial opportunities emanating from the identification of small molecule modulators of “novel” GPCRs (currently, GPCRs generate in excess of $25 billion per year in worldwide sales revenue [3]), it is not surprising that it is with great enthusiasm that both the pharmaceutical industry and academia move toward identifying novel members of this protein class.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Douglas, S. A., Ohlstein, E. H., and Johns, D. G. (2004) Cardiovascular pharmacology and drug discovery in the 21st century. Trends Pharmacol. Sci. 25, 225–233.
Bleicher, K. H., Bohm, H. J., Muller, K., and Alanine, A. I. (2003). Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Disc. 2, 369–378.
Robas, N., O’Reilly, M., Katugampola, S., and Fidock, M. (2003). Maximizing serendipity: strategies for identifying ligands for orphan G-protein-coupled receptors. Curr. Opin. Pharmacol. 3, 121–126.
Cacace, A., Banks, M., Spicer, T., Civoli, F., and Watson, J. (2003) An ultra-HTS process for the identification of small molecule modulators of orphan G-protein coupled receptors. Drug Disc. Today 8, 785–792.
Zhu, K., Baudhuin, L.M., Hong, G., (2001) Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J.Biol. Chem., 276, 41,325–41,335.
Kabarowski, J. H., Zhu, K., Le, L. Q., Witte, O. N., and Xu, Y. (2001) Zysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science, 293, 702–705.
Gräler, M. H. and Goetzl, E. J. (2002) Lysophospholipids and their G-protein coupled receptors in inflammation and immunity. Biochim. Biophys. Acta 1582, 168–174.
Xu, Y. (2002). Sphingosylphosphorylcholine and lysophosphatidylcholine: G-protein-coupled receptors and receptor-mediated signal transduction. Biochim.Biophys. Acta, 1582, 81–88.
Ross, R. (1999). Atherosclerosis: an inflammatory disease. New Engl. J. Med., 340, 115–126.
Frangogiannis, N.G., Smith, C.W., and Entman, M.L. (2002). The inflammatory response in myocardial infarction. Cardiovasc. Res., 53, 31–47.
Wilson, S., Bergsma, D.J., Chambers, J.K., (1998). Orphan G-protein-coupled receptors: the next generation of drug targets? Br. J. Pharmacol., 125, 1387–1392.
Lindsay, M.A. (2003). Target discovery. Nature Rev., 2, 831–838.
Holland, P.M., Abramson, R.D., Watson, R., and Gelfand, D.H. (1991). Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc. Natl Acad. Sci. USA 88, 7276–7280.
Heid, C.A., Stevens, J., Livak, K. J., and Williams, P.M. (1996). Real time quantitative PCR. Genome Res., 6, 986–994.
Sambrook, J., Fritsch, E.F., and Maniatis, T. (eds.) (1989) Molecular Cloning: ALaboratory Manual. Cold Spring Harbor Laboratory. Cold Spring Harbor, NY.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Douglas, S.A. et al. (2005). Quantitative Analysis of Orphan G Protein-Coupled Receptor mRNAs by TaqMan® Real-Time PCR. In: Davenport, A.P. (eds) Receptor Binding Techniques. Methods in Molecular Biology™, vol 306. Humana Press. https://doi.org/10.1385/1-59259-927-3:027
Download citation
DOI: https://doi.org/10.1385/1-59259-927-3:027
Publisher Name: Humana Press
Print ISBN: 978-1-58829-420-3
Online ISBN: 978-1-59259-927-1
eBook Packages: Springer Protocols